FDAsafety guidance66% confidence
FDA AP — KEYTRUDA (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA125514. Sponsor: MERCK SHARP DOHME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PEMBROLIZUMAB.
Supporting Context
- Therapeutic area
- Oncology · Renal Cell Carcinoma
- Sub-indication
- General
Related signal: FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC